SCHEMBL30765685

SCHEMBL30765685

CCCCOC(=O)Cn1c(-c2ccccc2F)nnc(N[C@H](C)c2ccc3oc4ccccc4c3c2)c1=O

nearest known ligand 0.41

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
MEN1 O00255 3/20 0.36
KMT2A Q03164 3/20 0.36
MAPT P10636 4/20 0.35
GPR139 Q6DWJ6 2/20 0.35
POLB P06746 1/20 0.34
SIRT3 Q9NTG7 1/20 0.34
LMNA P02545 2/20 0.33
MCHR1 Q99705 1/20 0.33
ALOX5 P09917 1/20 0.33
CYP1A2 P05177 1/20 0.33
CYP2C9 P11712 1/20 0.33
CYP2C19 P33261 1/20 0.33
KDM4E B2RXH2 1/20 0.33
HPGD P15428 1/20 0.33
HSD17B10 Q99714 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31558425 0.74 MEN1 (0.36) MEN1KMT2AGPR139LMNACYP2C9
SCHEMBL31558470 0.70 LMNA (0.37) GAAMEN1KMT2AGPR139POLB
SCHEMBL31558585 0.69 ALDH1A1 (0.35) GAAMEN1KMT2AMAPTPOLB
SCHEMBL31558409 0.66 POLB (0.36) MAPTPOLBLMNACYP1A2CYP2C9
SCHEMBL31558526 0.66 LMNA (0.34) MAPTLMNACYP2C9HPGD
SCHEMBL31558435 0.65 ELANE (0.45) LMNA
SCHEMBL31558449 0.64 CYP1A2 (0.38) GAAL3MBTL1MAPTPOLBLMNA
SCHEMBL20356854 0.62 MEN1 (0.52) GAAL3MBTL1MEN1KMT2APOLB
SCHEMBL31558541 0.62 SOS1 (0.39) POLBLMNAKDM4E
SCHEMBL31558524 0.62 ELANE (0.35) POLBLMNACYP1A2CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4568666-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS Alexion Pharmaceuticals, Inc. (US) 2025-06-18 EP disclosed
WO-2024035686-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ALEXION PHARMACEUTICALS, INC. (US) 2024-02-15 WO disclosed